<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1968">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05135546</url>
  </required_header>
  <id_info>
    <org_study_id>FORRIF</org_study_id>
    <nct_id>NCT05135546</nct_id>
  </id_info>
  <brief_title>Inhaled Recombinant Non-immunogenic Staphylokinase vs Placebo in Patients With COVID-19 - FORRIF Trial</brief_title>
  <acronym>FORRIF</acronym>
  <official_title>Inhaled Recombinant Non-immunogenic Staphylokinase vs Placebo in Patients With COVID-19 - FORRIF Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Supergene, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Russian Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Supergene, LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objective: to evaluate the tolerability, safety and efficacy of inhaled usage of the&#xD;
      Recombinant Non-immunogenic Staphylokinase (Fortelyzin®) vs placebo in patients with&#xD;
      COVID-19.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Fortelyzin® (the active substance Forteplase) is a recombinant non-immunogenic staphylokinase&#xD;
      with high fibrinselective thrombolytic activity. In a multicentre, randomised clinical trial&#xD;
      in patients with ST-segment elevation myocardial infarction (FRIDOM), non-immunogenic&#xD;
      staphylokinase was administered as a single intravenous bolus of 15 mg in all patients,&#xD;
      regardless of bodyweight, and showed similar high reperfusion patency and fewer minor&#xD;
      bleeding events compared with tenecteplase, as well as the absence of neutralising IgGs.&#xD;
      Results of the multicentre, randomised clinical trial in patients with an acute ischaemic&#xD;
      stroke (FRIDA) suggested that the non-immunogenic staphylokinase administrated as a single&#xD;
      intravenous bolus of 10 mg in all patients within the 4-5 h after the onset of symptoms is&#xD;
      non-inferior to alteplase. Mortality, symptomatic intracranial haemorrhage, and serious&#xD;
      adverse events did not differ between treatment groups (Gusev EI, Martynov MYu, Nikonov AA et&#xD;
      al. Non-immunogenic recombinant staphylokinase versus alteplase for patients with acute&#xD;
      ischaemic stroke 4-5 h after symptom onset in Russia (FRIDA): a randomised, open label,&#xD;
      multicentre, parallel-group, non-inferiority trial. Lancet Neurol. 2021; 20(9): 721-728).&#xD;
&#xD;
      Complex coagulation and hematologic abnormalities, including significantly elevated D-dimer&#xD;
      and fibrin/fibrinogen values are the distinct features identified in severe SARS-CoV-2. In&#xD;
      the list of antithrombotic therapy drugs in conjunction with anticoagulant and antiplatelet&#xD;
      therapy in patients with COVID-19, published by Liverpool Drug Interactions Group,&#xD;
      fibrinolytic therapy is also included.&#xD;
&#xD;
      So the main objectives of this study are to assess the tolerability, safety and efficacy of&#xD;
      inhaled usage of fibrinolytic agent the recombinant non-immunogenic staphylokinase&#xD;
      (Fortelyzin®) in patients with COVID-19.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2022</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>At clinical centers, patients will be randomly distributed by the &quot;envelope method&quot; into two groups to receive Fortelyzin® or placebo.&#xD;
The drugs will be administered after the signed informed consent. Fortelyzin® will be administered by inhalation of a dose of 15 mg.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Patients and study investigators will be blinded to subject treatment</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients discharged from the hospital with clinical status according to the WHO Ordinal Scale For Clinical Improvement - 3 points or less</measure>
    <time_frame>28 days post randomization</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients discharged from the hospital with clinical status according to the WHO Ordinal Scale For Clinical Improvement - 3 points or less</measure>
    <time_frame>14 days post randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital length of stay</measure>
    <time_frame>28 days post randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of ICU-free days</measure>
    <time_frame>28 days post randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of ventilation-free days</measure>
    <time_frame>28 days post randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of oxygen support-free days</measure>
    <time_frame>28 days post randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SpO2 level</measure>
    <time_frame>7, 14 and 28 days post randomization</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Recombinant nonimmunogenic staphylokinase lyophilisate for preparation of a solution for inhaled administration, 5 mg (745,000 IU) complete with a solvent. 15 mg (2,235,000 IU) - 3 vials, regardless of body weight.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Recombinant nonimmunogenic staphylokinase</intervention_name>
    <description>15 mg of drug reconstituted in 6 ml of 0.9% solution of NaCl for inhalation Other Name: Fortelyzin®</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>6 ml of 0.9% solution of NaCl for inhalation</description>
    <arm_group_label>Placebo control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men and women aged 18 and over&#xD;
&#xD;
          -  Clinical status according to the WHO scale - 6, 7, 8 and 9 points.&#xD;
&#xD;
          -  Verified respiratory infection COVID-19 by real-time PCR (quantitative)&#xD;
&#xD;
          -  Patient consent to use reliable contraceptive methods throughout the study and for 3&#xD;
             weeks after:&#xD;
&#xD;
               -  women who have a negative pregnancy test and use the following contraceptives:&#xD;
                  intrauterine devices, oral contraceptives, contraceptive patch, prolonged&#xD;
                  injectable contraceptives, double barrier method of contraception. Women who are&#xD;
                  not fertile can also take part in the study (documented conditions: hysterectomy,&#xD;
                  tubal ligation, infertility, menopause for more than 1 year);&#xD;
&#xD;
               -  men using barrier contraception. The study may also involve men who are not&#xD;
                  fertile (documented conditions: vasectomy, infertility)&#xD;
&#xD;
          -  Availability of signed and dated informed consent of the patient to participate in the&#xD;
             study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Clinical status according to the WHO scale - 1, 2, 3, 4 and 5 points.&#xD;
&#xD;
          -  Increased risk of bleeding:&#xD;
&#xD;
               -  extensive bleeding at the present time;&#xD;
&#xD;
               -  intracranial (including subarachnoid) hemorrhage at the present time.&#xD;
&#xD;
          -  Lactation, pregnancy&#xD;
&#xD;
          -  Known hypersensitivity to Fortelyzin®.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sergey S. Markin, MD, PhD</last_name>
    <phone>9067968906</phone>
    <phone_ext>+7</phone_ext>
    <email>amsemenof@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>City Clinical Hospital No.52</name>
      <address>
        <city>Moscow</city>
        <zip>123182</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <contact>
      <last_name>Georgyi N. Arbolishvili, MD, PhD</last_name>
      <phone>9265297133</phone>
      <phone_ext>+7</phone_ext>
      <email>geodoc@yandex.ru</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>N.V. Sklifosovsky Research Institute of Emergency Medicine</name>
      <address>
        <city>Moscow</city>
        <zip>129090</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <contact>
      <last_name>Vladimir V. Kulabukhov, MD, PhD</last_name>
      <phone>9255068081</phone>
      <phone_ext>+7</phone_ext>
      <email>vkulabukhov@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <results_reference>
    <citation>Gusev EI, Martynov MY, Nikonov AA, Shamalov NA, Semenov MP, Gerasimets EA, Yarovaya EB, Semenov AM, Archakov AI, Markin SS; FRIDA Study Group. Non-immunogenic recombinant staphylokinase versus alteplase for patients with acute ischaemic stroke 4·5 h after symptom onset in Russia (FRIDA): a randomised, open label, multicentre, parallel-group, non-inferiority trial. Lancet Neurol. 2021 Sep;20(9):721-728. doi: 10.1016/S1474-4422(21)00210-6.</citation>
    <PMID>34418399</PMID>
  </results_reference>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 24, 2021</study_first_submitted>
  <study_first_submitted_qc>November 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 26, 2021</study_first_posted>
  <last_update_submitted>November 25, 2021</last_update_submitted>
  <last_update_submitted_qc>November 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

